Login / Signup

Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.

Liang QiaoWei HeGuoying WangHuanwei ChenFuxi HuangBo ZhangYuxiong QiuShaoru LiuZhenkun HuangYichuan YuanJiliang QiuYichuan YuanBin-Kui Li
Published in: Cancer medicine (2024)
The combination of regorafenib and ICI shows potential as a viable second-line treatment for advanced HCC, exhibiting favorable efficacy while maintaining a tolerable safety profile in contrast to regorafenib monotherapy.
Keyphrases
  • metastatic colorectal cancer
  • combination therapy
  • magnetic resonance
  • randomized controlled trial
  • clinical trial
  • magnetic resonance imaging
  • computed tomography
  • risk assessment
  • human health